Nicole Galli

Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary Myelofibrosis

U. Gianelli, A. Iurlo, B. Martino, 2022, Cancers.

Trend of circulating CD34+ cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment

D. Consonni, A. Iurlo, D. Cattaneo, 2022, British journal of haematology.

Reply to: Can circulating CD34+ cells count be used for the prognosis of myelofibrosis? Probably yes, at least in patients treated with ruxolitinib

D. Consonni, A. Iurlo, D. Cattaneo, 2023, British journal of haematology.

Immunomodulatory cytokines and clonal dynamics in low‐risk myelodysplastic syndromes patients treated with luspatercept

N. Bolli, E. Fermo, W. Barcellini, 2023, American journal of hematology.